Other OTC - Delayed Quote • USD
QSAM Biosciences, Inc. (QSAM)
At close: 3:59 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. C. Richard Piazza MA, Ph.D. | Co-Founder & Executive Chairman | 125k | -- | 1948 |
| Mr. Douglas R. Baum | Co-Founder, CEO & Director | 125k | -- | 1968 |
| Mr. Christopher M. Nelson | General Counsel & Executive VP of Business Development | 100k | -- | 1970 |
| Mr. Adam King CPA | Chief Financial Officer | 208.2k | -- | 1986 |
| Ms. Namrata Chand | Vice President of Operations | -- | -- | 1981 |
QSAM Biosciences, Inc.
Plaza 1
Suite 500 9442 Capital of Texas Highway North
Austin, TX 78759
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4
Description
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas.
Corporate Governance
QSAM Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 11, 2024DEFM14C: Proxy StatementsSee Full Filing
- Mar 20, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 08, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 14, 20238-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 13, 2024 - May 18, 2024
QSAM Biosciences, Inc. Earnings Call
Related Tickers
0N6A.SG TME Pharma NV
0.2500
0.00%
0N6A.BE TME Pharma NV
0.2520
-3.45%
TLPPF Telix Pharmaceuticals Limited
9.65
-1.63%
CLRPF Clarity Pharmaceuticals Ltd
1.6900
-0.33%
EPRX Eupraxia Pharmaceuticals Inc.
2.8500
-2.40%
GSTC GlobeStar Therapeutics Corporation
0.0009
0.00%
TLX.AX Telix Pharmaceuticals Limited
14.88
+4.06%
CYCN Cyclerion Therapeutics, Inc.
3.0400
+7.42%
FENC Fennec Pharmaceuticals Inc.
9.16
+0.99%
BNOX Bionomics Limited
0.9663
+1.72%